Reverse Merger - Summary of Pro Forma Results of Operation (Detail) - OncoGenex Pharmaceuticals, Inc [Member] - USD ($) $ / shares in Units, $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2017 |
Dec. 31, 2016 |
|
| Business Acquisition [Line Items] | ||
| Revenue | $ 5,062 | |
| Net loss applicable to common shareholders | $ (20,111) | $ (21,363) |
| Net loss per share-basic and diluted | $ (4.19) | $ (7.79) |
| Weighted average shares | 4,794,421 | 2,743,906 |
| X | ||||||||||
- Definition Business acquisition pro forma earnings per share basic and diluted. No definition available.
|
| X | ||||||||||
- Definition Business acquisition pro forma weighted average shares. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|